Formation Bio launches US$600M fund to expand clinical-stage drug development portfolio

USA—US-based pharmaceutical company Formation Bio has launched a US$600 million Drug Development Accelerator Fund to acquire and advance promising medicines through clinical development, expanding its portfolio over the next three to five years.

The fund will support the acquisition or in-licensing of 10 to 15 drug programmes, primarily at Phase I and Phase II, from biotechnology and pharmaceutical companies.

Formation Bio will prioritise candidates targeting diseases with substantial unmet medical needs but limited industry investment, particularly those with a clear pathway to demonstrating clinical proof of concept.

Funding model targets clinical development

Formation Bio will deploy the capital through a hub-and-spoke model, with each drug programme held in a separate corporate entity.

The structure will allow individual assets to maintain distinct financial arrangements while sharing the company’s existing scientific, clinical and operational infrastructure.

Formation Bio will serve as the fund’s general partner through a wholly owned subsidiary and has committed its own capital alongside external limited partners.

Investors include hospitals, institutional endowments, research foundations and philanthropic organisations.

The company plans to achieve significant clinical milestones within two to four years of acquiring each programme, depending on its development requirements.

As clinical progress advances, it expects to pursue commercialisation or co-commercialisation agreements with pharmaceutical partners.

Benjamine Liu, co-founder and chief executive officer of Formation Bio, said the fund gives investors access to individual drug assets through a capital-efficient investment structure.

He added that the additional financing would allow Formation Bio to pursue more drug candidates, diversify its funding options and create opportunities to generate returns without selling the parent company.

The structure could also help reduce the company’s cost of capital over time.

AI infrastructure supports drug development strategy

Headquartered in New York City, with a second office in Boston, Formation Bio combines artificial intelligence, computational platforms and clinical trial operations to advance drug candidates.

The fund will leverage this existing infrastructure to assess potential acquisitions and manage development programmes.

By centralising scientific and operational resources, the company aims to reduce duplicated costs and direct more funding towards clinical research.

David Steinberg, chief business officer at Formation Bio, said the fund offers an alternative approach to advancing promising medicines that might otherwise remain inactive in pharmaceutical company pipelines.

Michael Ehlers, chief scientific officer and head of research and development, said the initiative would expand the company’s ability to apply AI to drug development and accelerate the progression of innovative therapies towards patients.

The fund introduces an investment model that separates individual drug assets from the traditional pharmaceutical company structure while retaining access to shared development capabilities.

For biotechnology companies and pharmaceutical firms seeking to divest or license programmes, the approach could provide another route for advancing clinical-stage candidates.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.